4767 results about "Intestino-intestinal" patented technology

A surgical stapler that may have a head assembly, a stapling assembly, a shield, a base head, a handle assembly, and a shaft assembly. A head assembly may have an anvil and anvil shaft, as well as a stapling assembly. A stapling assembly may have a trocar that can be removeably detachable with the anvil, a cannula extension, and a plurality of staples. A shield may be configured to retract from a first extended position where the shield generally covers the stapling assembly or the head assembly, to a second retracted position where the shield generally exposes the stapling assembly or the head assembly. The shield may be integral with the stapler, or provided after-market as an add-on. A surgical stapler may additionally or alternatively include an air or gas pump assembly that can be used to insufflate the rectum and intestinal tract during insertion and advancement of the stapler.

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and / or to develop and monitor the outcome of therapeutic treatments. An exemplary disease / condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Compositions including a non-pathogenic lactic acid-producing bacteria, such as a Bacillus species, spores or an extracellular product of B. coagulans, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome (SIDS) are also disclosed.

The invention relates to a lactobacillus microcapsule, a method for preparing the same, and the use of the same. The lactobacillus microcapsule consists of an outer layer of wall material, a freeze dried protective agent and lactobacilli. The invention also provides the method for preparing the lactobacillus microcapsule and the use of the lactobacillus microcapsule as a feed additive. The lactobacillus microcapsule can effectively protect the lactobacilli in a core material, prolong the survival time of the lactobacilli at room temperature and improve the tolerance of the lactobacilli to the metal ions in the feed; in addition, the lactobacillus microcapsule has good gastric acid resistance and can disintegrate in the intestinal canal quickly to release the lactobacilli, thereby improving the utilization rate of the lactobacilli, balancing the micro-ecological environment in the intestinal canal, suppressing the growth of pathogenic bacteria, protecting the health of the intestinal canals of animals, reducing the incidence rate of the intestinal canals of the animals and the like.

There is provided a method for controlling a flow of intestinal contents in the intestinal passageway of a patient's intestines. The method comprises gently constricting (i.e., without substantially hampering the blood circulation in the intestinal tissue wall) at least one portion of the intestinal tissue wall to influence the flow in the intestinal passageway, and stimulating the constricted wall portion to cause contraction of the wall portion to further influence the flow in the intestinal passageway. The method can be used for restricting or stopping the flow in the intestinal passageway, or for actively moving the fluid in the intestinal passageway, with a low risk of injuring the intestines.

The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and / or Escherichia coli and / or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and / or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.

The invention relates to a eubacterium and clostridium preparation and application of the same, in particular to a microecological preparation which is prepared for replenishing butyric acid bacteria and butyric acid produced by intestinal tract by taking single eubacterium, single clostridium or a eubacterium and clostridium composition as a main active composition, and application of the same in treating related diseases through butyric acid production, and belongs to the field of biological medicine.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and / or degraded within the GI tract.

The present invention discloses a fruit and vegetable probiotic tablet and a preparation method thereof. The fruit and vegetable probiotic tablet uses probiotic powders such as lactobacillus plantarum powder as the main raw material, and the preparation method scientifically mixes modified dietary fibers, fruit and vegetable powder, oligosaccharides, plant extracts, protein powder, tea leaf extracts and traditional Chinese medicine extracts and etc., thus improves the content of soluble celluloses which are of real significance for probiotic flora, enhances the physiological activity of celluloses, thereby increases the species of intestinal probiotic flora as well as significantly enhances the colonization ability and time of endogenous and exogenous probiotics in the human intestinal tracts, effectively inhibits the growth and reproduction of harmful intestinal bacteria, especially gram-negative bacteria, and fully regulates the composition of the intestinal probiotic flora. The prepared fruit and vegetable probiotic tablet has a high biological activity, a long human intestinal colonization time, and a significant weight loss effect, and is suitable for a wide range of people.

The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and / or degraded within the GI tract.

The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and / or an agent which inhibits intestinal drug degradation,wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and / or the agent which inhibits intestinal drug degradation.

Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and / or mixed glycerides and / or free fatty acids containing medium and / or long chain saturated, mono-unsaturated, and / or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron / lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic / non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e.g. urea, from the G.I. tract.

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention / treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention / treatment of colon cancer.

The invention provides a method for improving an intestinal colony structure and an application in the preparation of medicines, nourishment, health products, foods and beverages used for adjusting the intestinal colony. A high-flux sequence test technology and a multivariate statistical method are employed to find the intestinal colony groups which are closely related with host metabolism. According to the invention, berberine is taken as a sample to establish a novel method for improving the intestinal colony structure, the method comprises the steps of selectively increasing a part of bacteria, such as short chain aliphatic acid producing bacteria and the like, and simultaneously inhibiting a part of strain, such as bacteria capable of producing endotoxin and the like, thereby the disorders of metabolism or an immunization system due to enhancement of system inflammatory diseases induced by improper diet, obesity, insulin resistance and the like can be prevented or treated. The invention also provides a method for screening medicines, compounds and foods having the analogous effects, and a composition for improving the intestinal colony structure. The application of the method can be used for exploiting the medicines, nourishment, health products, foods, beverages and the like which take the intestinal colony as a target.

The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.

The invention discloses an enterococcus faecium EF08 as well as a feed additive and a feed containing the enterococcus faecium EF08. The enterococcus faecium EF08 is collected with the number of CGMCC (China General Microbiological Culture Collection Center) No.5549 in CGMCC. The feed additive disclosed by the invention can be used for reducing the feed excessively consumed by harmful bacteria in intestines by virtue of an equalizing effect of bacteria for equalizing the intestinal environment, furthermore, the conversion rate of the feed for economic animals is increased, the feed for the economic animals can be effectively converted into a primary animal product with an economic value, and then, the effect of increasing the economic values of the economic animals can be improved.

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and / or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

The invention specifically relates to a bifidobacterium microcapsule and a preparing method thereof. The bifidobacterium is obligatorily anaerobic and very sensitive to oxygen, PH, temperature, humidity, and other adverse external environment, thereby being very hard to remain activity during production, storage and transport; besides, if taken orally in a form of dry bifidobacterium powder, the bifidobacterium cannot tolerate low-pH value gastric acid, bile salt, and other environments, so a purpose that massive survived bifidobacteria arrive at an intestinal tract and colonise on the intestinal mucosa is hard to be guaranteed. The preparing method disclosed by the invention comprises the following steps of: adding freeze-dried bifidobacterium powder into a sodium alginate solution and then mixing in soybean oil, emulsifying the mixed solution and standing; centrifugally collecting micro-capsules; and drying the micro-capsules by using a vacuum freeze-drying technology. The bifidobacterium microcapsule disclosed by the invention has the advantages of gastric acid resistance, bile salt resistance and entericsolubility, high survival rate of bifidobacterium, simple preparation method, strong practicality, convenience for industrial production, and excellent storage stability and solves the problem of short storage period of probiotics preparations.

The invention discloses a detection system and method for intestinal flora and a dynamic database. The detection system for the intestinal flora comprises: an acquisition device, an analysis and processing device, a storage device and a data processing device, wherein the acquisition device is used for acquiring information of the intestinal flora; the analysis and processing device is used for carrying out amplification processing on the acquired information of intestinal flora to obtain data of intestinal flora at every time of individual detection; the storage device is used for storing the data of intestinal flora; and the data processing device is used for comparing the data of intestinal flora of individuals at each time with the total quantity of the intestinal flora in the storage device. According to the detection system, an examinee can know self intestinal health condition composition through detection of the intestinal flora, and the examinee can know a difference value between oneself and healthy crowd, and then regulates aspects of diet, exercise, living habits and the like, thereby improving the condition of the intestinal flora and the body health condition. According to the dynamic database, the capacity of the database can be expanded in real time to obtain detection parameters of excrement of different types of people at the newest period.

The present invention relates to a nutritional additive comprising arabinoxylans, which beneficially modulates the human intestinal flora. Furthermore, several food and beverage products comprising the additive are provided as well as methods to prepare the said additive.

The invention discloses a composition and an application thereof in regulating intestinal flora of animals. The composition contains aloe, probiotics and prebiotics, wherein the mass ratio of the aloe to the probiotics to the prebiotics is (6 to 3 to 1)-(6 to 1 to 3). The inventor discovers that the composition disclosed by the invention can effectively promote the proliferation of useful bacteria such as bifidobacterium and lactobacilli in animal intestines, so as to effectively regulate the intestinal flora of animals; therefore, the composition can be used for preventing or treating diabetes on the basis of the effect of the intestinal flora.

Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, are disclosed. Methods of treatment using the compositions are also disclosed. The material to be eliminated can include residual active antibiotics, metabolites, bacterial or other toxins, and drugs which cause side effects in the gastrointestinal tract. The adsorbents can be formulated in capsules, tablets or any acceptable pharmaceutical composition, and are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. The programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and / or colon.

Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

The invention belongs to the field of pharmacy and relates to a medicinal preparation taking esomeprazole magnesium as an active ingredient, in particular to an esomeprazole magnesium enteric-coated pellet and a preparation method thereof. According to the esomeprazole magnesium enteric-coated pellet, medicines can be rapidly released in intestinal tracts. The esomeprazole magnesium enteric-coated pellet comprises the following structural layers in sequence from inside to outside: a medicine-contained layer, an isolation layer and an enteric-coated layer.